Summit Therapeutics (SMMT) Assets (2020 - 2026)
Summit Therapeutics' (SMMT) quarterly Assets came in at $752.2 million in Q2 2026, up 132.13% YoY from $324.0 million in Q2 2025, and up 16.1% on a QoQ basis from $647.9 million in Q1 2026.
Summit Therapeutics (SMMT) Assets (2020 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 7 years of Assets data on file, last reported at $752.2 million in Q2 2026.
- Quarterly Assets rose 132.13% year-over-year to $752.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $752.2 million (up 132.13% YoY) and the FY2025 annual result came in at $751.2 million, up 72.46% from the prior year.
- Assets advanced to $752.2 million in Q2 2026, from $647.9 million in the prior quarter.
- In the past five years, Assets ranged from a high of $752.2 million in Q2 2026 to a low of $95.7 million in Q2 2022.
- A 5-year average of $362.4 million and a median of $292.9 million in 2025 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets soared 485.82% — and 2023, when it slumped 69.44%.
- Tracing SMMT's Assets over 5 years: stood at $664.2 million in 2022, then tumbled by 69.44% to $202.9 million in 2023, then soared by 114.62% to $435.6 million in 2024, then surged by 72.46% to $751.2 million in 2025, then advanced by 0.13% to $752.2 million in 2026.
- The last three Assets figures came in at $752.2 million (Q2 2026), $647.9 million (Q1 2026), and $751.2 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 752.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 752.19 Mn |
| Mar 31, 2026 | 647.86 Mn |
| Dec 31, 2025 | 751.18 Mn |
| Sep 30, 2025 | 261.73 Mn |
| Jun 30, 2025 | 324.04 Mn |
| Mar 31, 2025 | 383.82 Mn |
| Dec 31, 2024 | 435.56 Mn |
| Sep 30, 2024 | 502.85 Mn |
| Jun 30, 2024 | 341.86 Mn |
| Mar 31, 2024 | 176.78 Mn |
| Dec 31, 2023 | 202.95 Mn |
| Sep 30, 2023 | 218.48 Mn |
| Jun 30, 2023 | 237.37 Mn |
| Mar 31, 2023 | 254.90 Mn |
| Dec 31, 2022 | 664.17 Mn |
| Sep 30, 2022 | 155.33 Mn |
| Jun 30, 2022 | 95.72 Mn |
| Mar 31, 2022 | 116.47 Mn |
| Dec 31, 2021 | 113.37 Mn |
| Sep 30, 2021 | 128.67 Mn |